Brenus Pharma has announced what it says are two groundbreaking presentations on STC-1010, the company’s first drug candidate for colorectal cancer (CRC), produced by Brenus Pharma’s STC (stimulated tumor cell) technology platform.
Innovative models for anti-tumor vaccine development are highlighted: Inovotion’s in-ovo CAM (chorioallantoic model) assay and Explicyte’s ex-vivo co-culture assay, are used to characterize the mechanism of action through specific immune responses, and validate the anti-tumor effects of STC- 1010.
Brenus Pharma says this model demonstrates the potential of STC-1010 in the clinical setting for the treatment of patients with colorectal cancer.
The first study evaluated the safety and efficacy of STC-1010 in activating an antitumoral immune response against human colorectal adenocarcinoma using the chicken CAM assay. The results obtained in-ovo confirm the anti-tumor efficacy – mediated by cytokine secretion and T-cell expansion – of the vaccine previously observed in a CRC syngeneic mouse model. STC-1010 prioritized dendritic cells will induce a multispecific pool of tumor-fighting T lymphocytes without toxicity.
The second study evaluated the functional activity of STC-1010 primed dendritic cells (DC) from isolated human PBMC donors, to activate autologous CD8+ T cells and promote tumor cell death. This study evaluates the cross-priming and specificity of the immune response induced by STC-1010.
The results demonstrated that STC-1010 is an efficient strategy for educating the immune system by crossing DCs and increasing specific CD8+ T cell activity (TCR sequencing) all of which promoted the significant tumor killing observed ex-vivo.
Taken together, the companies say the studies provide promising results for the development of STC-1010 and prove its potential to serve into clinical settings for the treatment of patients with CRC.
The presentation was made at the American Association for Cancer Research (AACR) annual conference, in Orlando, USA, earlier this month.